Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Establishes a Hepatitis C Elimination Program at HHS with a national strategy, advisory committee, interagency working group, public dashboard, and annual reports. Creates a 5-year subscription purchasing program for direct-acting antiviral hepatitis C drugs to provide no-cost treatment to defined covered populations.
Progressives emphasize equity and elimination; conservatives emphasize federal cost and procurement overreach.
Relative to its intended legislative type, this bill is a detailed substantive policy proposal that combines statutory program creation, funding, procurement authority, and modifications to existing benefit and drug-pricing law to expand access to hepatitis C treatment for defined populations.
Establishes a Hepatitis C Elimination Program at HHS with a national strategy, advisory committee, interagency working group, public dashboard, and annual reports.
Creates a 5-year subscription purchasing program for direct-acting antiviral hepatitis C drugs to provide no-cost treatment to defined covered populations.
Authorizes grants to states, community providers, correctional systems, tribal and safety-net programs, funds point-of-care testing development, and eliminates Medicare Part D cost-sharing for hepatitis C antivirals for plan years 2027–2031.
Policy is technically focused and non-ideological, aiding support, but multi‑billion appropriations and drug program changes raise barriers.
Relative to its intended legislative type, this bill is a detailed substantive policy proposal that combines statutory program creation, funding, procurement authority, and modifications to existing benefit and drug-pricing law to expand access to hepatitis C treatment for defined populations.
Progressives emphasize equity and elimination; conservatives emphasize federal cost and procurement overreach.
These are examples from the analysis, not a ranked list of the most-affected groups.
Progressives emphasize equity and elimination; conservatives emphasize federal cost and procurement overreach.
Likely strongly supportive: treats hepatitis C as a preventable, curable public-health problem and removes financial barriers for vulnerable groups.
Values funding for elimination, incarcerated people, uninsured, tribal programs, and Medicare cost-sharing removal.
Generally favorable but pragmatic: supports a measurable elimination plan and price-leveraging subscription buys, while wary of fiscal costs, implementation complexity, and state uptake.
Wants performance oversight and clarity on interactions with existing programs.
Skeptical or opposed: critiques center on federal spending, procurement centralization, and expanded federal involvement in drug purchasing and distribution.
Some support possible for targeted public-safety benefits, like treating incarcerated individuals.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
Policy is technically focused and non-ideological, aiding support, but multi‑billion appropriations and drug program changes raise barriers.
The bill has not accumulated any surfaced votes yet.
Progressives emphasize equity and elimination; conservatives emphasize federal cost and procurement overreach.
Policy is technically focused and non-ideological, aiding support, but multi‑billion appropriations and drug program changes raise barriers.
Relative to its intended legislative type, this bill is a detailed substantive policy proposal that combines statutory program creation, funding, procurement authority, and modifications to existing benefit and drug-pri…
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.